Potentiating effect of inhaled acetaldehyde on bronchial responsiveness to methacholine in asthmatic subjects

Shigebaru Myou, Masaki Fujimura, Kohichi Nishi, Masako Matsuda, Takio Ohka, Tamotsu Matsuda

Abstract

Background – It has recently been reported that acetaldehyde induces bronchoconstriction indirectly via histamine release. However, no study has been performed to assess whether acetaldehyde worsens bronchial responsiveness in asthmatic subjects so this hypothesis was tested.

Methods – Methacholine provocation was performed on three occasions: (1) after pretreatment with oral placebo and inhaled saline (P-S day), (2) after placebo and inhaled acetaldehyde (P-A day), and (3) after a potent histamine H1 receptor antagonist terfenadine and acetaldehyde (T-A day) in a double blind, randomised, crossover fashion. Nine asthmatic subjects inhaled 0.8 mg/ml acetaldehyde or saline for four minutes. After each inhalation a methacholine provocation test was performed.

Results – Methacholine concentrations producing a 20% fall in FEV1 (PC20-MCh) on the P-A day (0.48 mg/ml, 95% CI 0.21 to 1.08) and T-A day (0.41 mg/ml, 95% CI 0.22 to 0.77) were lower than those on the P-S day (0.85 mg/ml, 95% CI 0.47 to 1.54). There was no change in the PC20-Mch between the P-A and T-A days. A correlation was observed between the logarithmic values of PC20-MCh (log PC20-MCh) on the P-S day and the potentiating effect of acetaldehyde on the methacholine responsiveness [(log PC20-MCh on P-A day) – (log PC20-MCh on P-S day)] (rho = 0.82).

Conclusions – Acetaldehyde induces bronchial hyperresponsiveness in patients with asthma by mechanisms other than histamine release.

(Thorax 1994;49:644-648)

Exacerbation of asthmatic symptoms by alcoholic drinks or ethanol induced bronchoconstriction has been observed among 55% of Japanese asthmatic patients.1 Ethanol is not considered a bronchoconstrictor in Japanese patients,12 while alcohol in itself is a bronchoconstrictor and a bronchodilator when given either orally or by inhalation in the white population.18-9

Ethanol is oxidised to acetaldehyde which, in turn, is oxidised to acetate mainly by aldehyde dehydrogenase (ALDH). This consists of two main isozymes with low and high Michaelis–Menten constant (the substrate concentration at which an enzyme catalysed reaction proceeds at one half its maximum velocity) for acetaldehyde.14—8 About 50% of Japanese people lack the enzyme with a low Michaelis–Menten constant (ALDH 2) and show an elevation of serum acetaldehyde concentration due to their inability to metabolise acetaldehyde quickly and effectively.19—11 It has been reported that ALDH 2 activity is a major determining factor of asthmatic exacerbations after drinking pure ethanol or alcoholic beverages in Japanese asthmatic subjects, and that changes in specific airway conductance are closely related to blood acetaldehyde levels.2 We recently showed that inhaled acetaldehyde causes bronchoconstriction indirectly via histamine release in asthmatics,12 and that the release of histamine made a major contribution to bronchoconstriction provoked after oral administration of alcohol (unpublished data). These findings suggest that acetaldehyde plays an important part in ethanol induced bronchoconstriction in Japanese asthmatic patients.

On the other hand, the severity of bronchial hyperresponsiveness correlates closely with the severity of symptoms,13—14 with the amount of treatment required to control symptoms,15 and with the diurnal variation of airway function.16 No study has been performed, however, to investigate the effect of acetaldehyde on bronchial responsiveness in asthmatic subjects.

We wished to determine (1) whether bronchial responsiveness to inhaled methacholine was altered when asthmatic subjects inhaled a subthreshold concentration of aerosolised acetaldehyde which did not cause bronchoconstriction per se, and (2) whether any increase in bronchial hyperresponsiveness after acetaldehyde was mediated by histamine release.

Methods

Subjects

Nine asthmatic patients with a mean (SE) age of 46.1 (6.7) years participated in the study (table 1). None had ever smoked and all had avoided respiratory tract infection for at least eight weeks before the study. Each patient satisfied the American Thoracic Society definition of asthma.17

The study was carried out when their symptoms were mild and stable while they were taking an aerosol β2 agonist, oral theophylline, or both. They had not received treatment with steroids for at least eight weeks. Informed
Potentiation of bronchial responsiveness by acetaldehyde

Table 1 Subject characteristics

<table>
<thead>
<tr>
<th>Subject no.</th>
<th>Age (years)</th>
<th>Sex</th>
<th>IgE (IU/ml)</th>
<th>FVC (% predicted)</th>
<th>FEV₁ (% predicted)</th>
<th>FEV₁/FVC (%)</th>
<th>PC₂₀-AcCHO (mg/ml)</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1*</td>
<td>66</td>
<td>M</td>
<td>870</td>
<td>105-8</td>
<td>89-6</td>
<td>66-9</td>
<td>30-5</td>
<td>Sa</td>
</tr>
<tr>
<td>2*</td>
<td>27</td>
<td>M</td>
<td>100</td>
<td>117-7</td>
<td>79-6</td>
<td>62-3</td>
<td>12-8</td>
<td>Sa, Th</td>
</tr>
<tr>
<td>3*</td>
<td>29</td>
<td>M</td>
<td>2300</td>
<td>105-9</td>
<td>78-7</td>
<td>68-2</td>
<td>30-8</td>
<td>Sa, Th</td>
</tr>
<tr>
<td>4*</td>
<td>22</td>
<td>F</td>
<td>590</td>
<td>86-0</td>
<td>77-7</td>
<td>83-3</td>
<td>20-9</td>
<td>Sa</td>
</tr>
<tr>
<td>5*</td>
<td>29</td>
<td>M</td>
<td>28</td>
<td>110-0</td>
<td>78-3</td>
<td>66-0</td>
<td>21-2</td>
<td>Sa, Th</td>
</tr>
<tr>
<td>6</td>
<td>51</td>
<td>M</td>
<td>22</td>
<td>70-0</td>
<td>85-1</td>
<td>66-6</td>
<td>21-6</td>
<td>Sa, Th</td>
</tr>
<tr>
<td>7</td>
<td>73</td>
<td>M</td>
<td>1800</td>
<td>83-7</td>
<td>83-3</td>
<td>67-2</td>
<td>18-6</td>
<td>Sa, Th</td>
</tr>
<tr>
<td>8</td>
<td>51</td>
<td>F</td>
<td>39</td>
<td>104-5</td>
<td>71-9</td>
<td>69-9</td>
<td>24-7</td>
<td>Th</td>
</tr>
<tr>
<td>9</td>
<td>68</td>
<td>F</td>
<td>10</td>
<td>87-0</td>
<td>100-0</td>
<td>80-0</td>
<td>38-4</td>
<td>Th</td>
</tr>
<tr>
<td>Mean</td>
<td>46-2</td>
<td></td>
<td>639-9</td>
<td>96-7</td>
<td>82-9</td>
<td>69-0</td>
<td>23-3</td>
<td></td>
</tr>
<tr>
<td>SE</td>
<td>9-6</td>
<td></td>
<td>287-8</td>
<td>84-8</td>
<td>76-8</td>
<td>63-2</td>
<td>18-2</td>
<td></td>
</tr>
<tr>
<td>95% CI lower</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>95% CI upper</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sa = salbutamol via metered dose inhaler; Th = oral theophylline; FVC = forced vital capacity; FEV₁ = forced expiratory volume in one second; PC₂₀ = AcCHO = acetaldehyde concentration producing a 20% fall in FEV₁.

consent was obtained from all subjects. This study was approved by the ethics committee of our hospital.

STUDY PROTOCOL
Non-specific bronchial responsiveness was measured on three occasions, each two weeks apart: (1) after pretreatment with oral placebo and inhaled saline (P-S day), (2) after placebo and inhaled acetaldehyde (P-A day), and (3) after a potent histamine H₁ receptor antagonist, terfenadine and acetaldehyde (T-A day) in a double blind, randomised, crossover fashion. Terfenadine was given orally in a dose of 60 mg twice a day for three days and at 08.00 and 13.00 hours on the fourth (test) day. Placebo was administered by the same procedure as terfenadine. All medication, except for pretreatment with terfenadine and placebo, was stopped at 13.00 hours on the day before the test day to allow a washout time of at least 24 hours. The bronchial responsiveness to inhaled acetaldehyde was then measured at 15.00 hours on the test day.

AEROSOLISED ADMINISTRATION OF ACETALDEHYDE OR SALINE
An acetaldehyde concentration producing a 20% fall in FEV₁ (PC₂₀-AcCHO) was determined as previously described¹² (table 1). Acetaldehyde was dissolved in physiological saline to make a solution of 0·8 mg/ml, the subthreshold concentration having no direct bronchoconstrictor effect itself in a preliminary study. Acetaldehyde and saline were inhaled from a DeVilbiss 646 nebuliser (DeVilbiss, Somerset, Pennsylvania, USA) operated by compressed air at 5 l/min. The nebuliser output was 0·14 ml/min. Each solution was inhaled for four minutes by tidal breathing with the nebuliser while wearing a noseclip, and this was followed immediately by measurements of FEV₁.

MEASUREMENT OF BRONCHIAL RESPONSIVENESS
Non-specific bronchial responsiveness was evaluated by methacholine challenge. Methacholine chloride was dissolved in physiological saline solution to make concentrations of 0·04, 0·08, 0·16, 0·31, 0·63, 1·25, 2·5, 5, 10, and 20 mg/ml. Saline and methacholine were inhaled from a DeVilbiss 646 nebuliser operated by compressed air at 51/min. Saline was inhaled first for two minutes and FEV₁ measured. If the change in FEV₁ from the baseline value was ≤10% inhalation of methacholine was started, and if the saline solution caused a change in FEV₁ of >10% the test was stopped or postponed. Methacholine was inhaled for two minutes by tidal breathing and followed immediately by measurements of FEV₁. Increasing concentrations of methacholine were inhaled until a fall of 20% or more in FEV₁ occurred. These values were plotted on a semilogarithmic graph paper and a methacholine concentration producing a 20% fall in FEV₁ (PC₂₀-MCh) was determined from the post saline FEV₁ value before the first inhalation of methacholine. FEV₁ was measured three times and the best value of three attempts was recorded each time.

DATA ANALYSIS
FEV₁ data were expressed as mean and 95% confidence intervals (95% CI). Analysis of variance (ANOVA) was used for differences in baseline FEV₁ between the three test days. FEV₁ values and percentage changes in FEV₁ from the preinhalation value after inhalation of either acetaldehyde or saline were also analysed by ANOVA. PC₂₀-MCh values were logarithmically transformed for analysis and reported as the geometric mean (95% CI). ANOVA followed by Fisher's protected least significant difference was used to analyse changes in PC₂₀-MCh induced by treatment with acetaldehyde or saline. The degree of augmentation of methacholine responsiveness by acetaldehyde (ΔPC₂₀-MCh) was calculated as the difference between the logarithmic values of PC₂₀-MCh on the P-A and P-S days, and the logarithmic value of PC₂₀-MCh on the P-S day was used as the baseline bronchial responsiveness. Correlations were obtained using Spearman's non-parametric rank correlation. A value of p < 0·05 was accepted for statistical significance.

Results
Baseline FEV₁ and percentage changes in FEV₁ from the baseline value induced by inha-
luation of either saline or acetaldehyde are shown in Table 2. Mean (95% CI) FEV₁ values after inhalation of saline or acetaldehyde were 2.34 (1.83 to 2.84) l after saline on P-S day, 2.33 (1.84 to 2.82) l after acetaldehyde on P-A day, and 2.38 (1.89 to 2.87) l after acetaldehyde on T-A day. There were no significant differences in the FEV₁ at baseline or after inhalations between any pair of three test days. There were no significant changes in FEV₁ after inhalation of each solution.

Acetaldehyde inhalation significantly increased bronchial responsiveness to methacholine (Fig 1). The geometric mean (95% CI) PC₂₀-MCh significantly decreased (p < 0.05) from 0.85 (0.47 to 1.54) mg/ml on P-S day to 0.48 (0.21 to 1.08) mg/ml on P-A day (a change of 0.84 (0.42 to 1.25) doubling doses), and to 0.41 (0.22 to 0.77) mg/ml (1.05 (0.38 to 1.71) doubling doses) on T-A day. The PC₂₀-MCh values on T-A and P-A days were identical. The changes in bronchial responsiveness were similar in the four patients who had never experienced alcohol-induced asthma and in the five who had.

Logarithmic values of PC₂₀-AcCHO related to logarithmic values of PC₂₀-MCh on P-S day (rho = 0.93, p < 0.01) (Fig 2) and a significant correlation was observed between logarithmic values of PC₂₀-MCh on P-S day and the potentiating effect of acetaldehyde on methacholine responsiveness (ΔPC₂₀-MCh) (rho = 0.82, p < 0.05) (Fig 3).

Discussion

The results of this study show that the sub-threshold concentration of acetaldehyde caused an increase in non-specific bronchial hyperresponsiveness in asthma, and that this was related to the baseline bronchial hyperresponsiveness. Furthermore, terfenadine had no inhibitory effect on the acetaldehyde induced bronchial hyperresponsiveness.

It has been reported that acetaldehyde increases the blood and urine levels of catecholamines,¹⁸,²⁰ and that adrenaline causes bronchodilatation.²¹ In this study we chose aerosol administration of acetaldehyde in order to examine the direct effect of acetaldehyde on airways, excluding the sympathomimetic action and the effect of ALDH 2.

---

Table 2  Baseline values of FEV₁, in litres and percentage change after inhalation

<table>
<thead>
<tr>
<th>Subject no.</th>
<th>Oral placebo + inhaled saline (P-S)</th>
<th>Oral placebo + inhaled acetaldehyde (P-A)</th>
<th>Oral terfenadine + inhaled acetaldehyde (T-A)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>% change</td>
<td>Baseline</td>
</tr>
<tr>
<td>1</td>
<td>2.45</td>
<td>5.5</td>
<td>2.48</td>
</tr>
<tr>
<td>2</td>
<td>3.21</td>
<td>-3.4</td>
<td>3.18</td>
</tr>
<tr>
<td>3</td>
<td>2.94</td>
<td>10</td>
<td>3.16</td>
</tr>
<tr>
<td>4</td>
<td>2.49</td>
<td>-20</td>
<td>2.49</td>
</tr>
<tr>
<td>5</td>
<td>3.01</td>
<td>4.7</td>
<td>2.76</td>
</tr>
<tr>
<td>6</td>
<td>1.90</td>
<td>-16</td>
<td>2.06</td>
</tr>
<tr>
<td>7</td>
<td>1.74</td>
<td>-11</td>
<td>1.71</td>
</tr>
<tr>
<td>8</td>
<td>1.65</td>
<td>12</td>
<td>1.71</td>
</tr>
<tr>
<td>9</td>
<td>1.52</td>
<td>-26</td>
<td>1.44</td>
</tr>
<tr>
<td>Mean</td>
<td>2.32</td>
<td>5.4</td>
<td>2.33</td>
</tr>
<tr>
<td>95% CI lower</td>
<td>1.83</td>
<td>-20</td>
<td>1.84</td>
</tr>
<tr>
<td>95% CI upper</td>
<td>2.82</td>
<td>28</td>
<td>2.82</td>
</tr>
</tbody>
</table>
Potentiation of bronchial responsiveness by acetaldehyde

The morning after drinking alcoholic beverages exacerbation of asthmatic symptoms is observed in some Japanese asthmatic patients. The severity of bronchial hyperresponsiveness correlates closely with the severity of symptoms.\(^1\)\(^2\) We therefore investigated whether acetaldehyde has a potentiating effect on methacholine responsiveness. Our data (fig 1) show that a subthreshold concentration of acetaldehyde causes bronchial hyperresponsiveness to methacholine. It suggests the need for more research to examine whether a dietary factor influences bronchial reactivity in asthmatic subjects, both with and without a history of alcohol-induced bronchoconstriction, in order to control symptoms.

It has been reported that acetaldehyde causes dose dependent histamine release from leucocytes in Japanese asthmatics in vitro.\(^3\)\(^4\) We have recently shown that acetaldehyde causes bronchoconstriction indirectly via histamine release in asthmatic subjects.\(^5\) Histamine does not generally influence reactivity to methacholine. Indeed, histamine has been shown to have no effect on radioligand binding to muscarinic receptors,\(^6\) and terfenadine failed to protect the airways against the constrictor effect of inhaled methacholine.\(^7\)\(^8\) Histamine, however, is a potent inducer of prostaglandin synthesis.\(^9\)\(^10\) As it could not be excluded that secondary products of acetaldehyde induced endogenous histamine cause bronchial hyperresponsiveness, we considered whether augmentation of bronchial responsiveness after inhalation of acetaldehyde is associated with release of endogenous histamine. However, terfenadine failed to prevent the acetaldehyde induced bronchial hyperresponsiveness (fig 1).

In the present study terfenadine was administered at sufficient doses to inhibit acetaldehyde induced bronchoconstriction which is caused via histamine release.\(^11\) In addition, terfenadine is a potent and selective histamine \(H_1\) receptor antagonist and does not possess anticholinergic, antiserotonergic, or antiadrenergic properties.\(^12\)\(^13\) It indicates that histamine and \(H_1\) receptor mediated secondary reactions are not responsible for acetaldehyde induced bronchial hyperresponsiveness.

We have recently shown a significant correlation between the bronchial responsiveness to acetaldehyde and the bronchial responsiveness to methacholine,\(^12\) which was reconfirmed in the present study (fig 2), and that FEV, was not altered by acetaldehyde inhalation in healthy subjects. In the present study the degree of increased bronchial hyperresponsiveness induced by acetaldehyde was related to the baseline bronchial hyperresponsiveness (fig 3). It suggests that bronchial hyperresponsiveness is a necessary precondition for the expression of bronchial hyperresponsiveness induced by acetaldehyde.

Four asthmatic subjects in our group had no history of alcohol induced asthma, and inhalation of acetaldehyde tended to increase bronchial responsiveness (p < 0.1). This effect may be non-specific, and may result in an elevation of serum acetaldehyde concentration due to the inability of ALDH 2 to play an important part in ethanol induced asthma. However, the small number of subjects in this study make it difficult to reach a firm conclusion.

In conclusion, the subthreshold concentration of acetaldehyde increases non-specific bronchial responsiveness in asthmatic subjects, and the acetaldehyde induced bronchial hyperresponsiveness observed in asthmatics could be an important factor in the pathogenesis of bronchial hyperresponsiveness.

16 Ryan G, Latimer KM, Dolovich J, Hargrave FE. Bron-
17 American Thoracic Society. Standard for diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:229-44.
Potentiating effect of inhaled acetaldehyde on bronchial responsiveness to methacholine in asthmatic subjects.

S Myou, M Fujimura, K Nishi, M Matsuda, T Ohka and T Matsuda

Thorax 1994 49: 644-648
doi: 10.1136/thx.49.7.644

Updated information and services can be found at:
http://thorax.bmj.com/content/49/7/644

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/